<DOC>
	<DOCNO>NCT01414920</DOCNO>
	<brief_summary>The purpose study determine efficacy safety TAK-875 , daily ( QD ) , combination sitagliptin QD participant type 2 diabetes mellitus ( T2DM ) .</brief_summary>
	<brief_title>Efficacy Safety TAK-875 Combination With Sitagliptin Participants With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>TAK-875 develop Takeda Global Research Development , Inc. adjunct diet exercise improve glycemic control patient T2DM . Sitagliptin inhibitor dipeptidyl peptidase-4 ( DPP-4 ) approve adjunct diet exercise improve glycemic control adult T2DM . This study investigate effect combination TAK-875 DDP-4 inhibitor glycosylated hemoglobin reduction .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . The participant either : A historical diagnosis Type 2 Diabetes ( T2DM ) without chronic use ( define &gt; 7 day ) antidiabetic therapy within 8 week prior Screening , least 8week documented history diet exercise plan Screening OR , A historical diagnosis T2DM stable least 1500 mg per day ( maximum tolerate dose ) metformin monotherapy least 8 week Screening . Participants stable dose metformin enter study continue dose metformin throughout duration study . 4 . The participant man woman age 18 80 year , inclusive . 5 . The participant 's body mass index ( BMI ) ( kg/m2 ) Screening ≥23 ≤45 . 6 . The participant glycosylated hemoglobin ( HbA1c ) level Screening 7.5 % 10.0 % , inclusive , metformin 7.5 % 10.9 % , inclusive , treat diet exercise alone . 7 . The participant fasting plasma glucose level &lt; 14.4 mmol/L ( &lt; 260 mg/dL ) , Screening . 8 . The participant fasting Cpeptide concentration ≥0.26 nmol/L ( ≥0.8 ng/mL ) Screening . 9 . If participant take chronic , nonexcluded medication , dose medication must stable ( change dose drug ) least 4 week prior Screening . 10 . The participant able willing monitor glucose level home glucose monitor consistently record blood glucose concentration accord give instruction . 11 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 30 day last dose . 12 . A female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent throughout duration study . 13 . A female participant childbearing potential must negative serum human chorionic gonadotropin ( HCG ) pregnancy test Screening ( Visit 1 ) Placebo Runin ( Visit 2 ) . A negative urine HCG pregnancy test also require Randomization ( Visit 3 ) , prior administration first dose doubleblind study medication . 14 . The participant 's compliance singleblind study medication runin phase least 80 % exceed 120 % base tablet count perform study staff . 1 . The participant receive investigational compound within 4 week prior Screening . 2 . The participant enrol previous TAK875 study . 3 . The participant immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 4 . The participant history hypersensitivity allergy TAK875 sitagliptin , excipients . 5 . The participant history drug abuse ( define illicit drug use ) history alcohol abuse within 2 year prior Screening visit . 6 . The participant history cancer remission &lt; 5 year prior Screening ( history basal cell carcinoma stage 1 squamous cell carcinoma skin allow ) . 7 . The participant systolic blood pressure ≥150 mm Hg diastolic pressure ≥90 mm Hg Screening ( Visit 1 ) Baseline ( Visit 3 ) ( confirm repeat measurement 30 minute initial measurement ) . 8 . The participant creatine phosphokinase ( CPK ) level ≥5x upper limit normal ( ULN ) Screening . 9 . The participant hemoglobin level ≤12 g/dL ( 120 gm/L ) men ≤10 g/dL ( 100 gm/L ) woman Screening . 10 . The participant ALT and/or AST level ≥2.5x ULN Screening . 11 . The participant total bilirubin level &gt; ULN Screening . 12 . The participant serum triglyceride concentration ≥4.5 mmol/L ( ≥400 mg/dL ) Screening . 13 . The participant estimate glomerular filtration rate ≤60mL/min use Modification Diet Renal Disease ( MDRD ) equation Screening . 14 . The participant document history concurrent sign uncontrolled ( euthyroid ) thyroid disease ( eg , autoimmune thyroid diseases Graves disease Hashimoto thyroiditis active thyroid nodule ) . 15 . The participant history pancreatitis . 16 . The participant history laser treatment proliferative diabetic retinopathy within 6 month prior Screening . 17 . The participant history gastric bypass surgery diabetic gastroparesis investigator 's opinion moderate severe hence may impair absorption study medication . 18 . The participant coronary angioplasty , coronary stent placement , coronary bypass surgery , myocardial infarction , unstable angina pectoris , clinically significant abnormal electrocardiogram ( ECG ) , cerebrovascular accident transient ischemic attack within 6 month prior Screening . 19 . The participant history hemoglobinopathy may affect determination HbA1c . 20 . The participant positive test result hepatitis B surface antigen antibody hepatitis C virus , and/or know history human immunodeficiency virus Screening . 21 . The participant donate receive blood product within 12 week prior Screening . 22 . The participant received medication prior Screening list excluded Medications section . 23 . If female , participant pregnant lactate intend become pregnant , , within 1 month participate study ; intend donate ova time period . 24 . If male , participant intend donate sperm course study 30 day thereafter . 25 . The participant physical psychiatric disease condition judgment investigator may affect life expectancy may make difficult successfully manage follow participant accord protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>